← All Signals

🏥 FDA: The Harvard Drug Group LLC — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-03-26Date

Summary

Defective blister packaging for Midodrine tablets creates patient safety risks and suggests packaging process failures at Major Pharmaceuticals. This could lead to temporary shortages of this blood pressure medication and increased regulatory oversight.

Actionable: Verify inventory of Midodrine tablets and check packaging integrity before distribution.

AI Confidence: 80%

Data Points

firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now